Udomsinprasert W, Honsawek S, Poovorawan Y. Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol 2018; 10(10): 708-718 [PMID: 30386464 DOI: 10.4254/wjh.v10.i10.708]
Corresponding Author of This Article
Yong Poovorawan, MD, Professor, Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, 1873 Rama IV Road Patumwan, Bangkok 10330, Thailand. yong.p@chula.ac.th
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Wanvisa Udomsinprasert, Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand
Sittisak Honsawek, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
Yong Poovorawan, Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
Author contributions: Udomsinprasert W, Honsawek S and Poovorawan Y contributed to the work, conceived and designed this review; Udomsinprasert W generated the figure and wrote the manuscript, Udomsinprasert W, Honsawek S and Poovorawan Y reviewed and edited the manuscript; all authors reviewed and approved the final manuscript.
Supported byThe Research Chair Grant from NSTDA, No. P-15-50004; the Center of Excellence in Clinical Virology, No. GCE 59-00930-005; and Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and Hospital.
Conflict-of-interest statement: The authors declare that they have no competing interests regarding the publication of this paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yong Poovorawan, MD, Professor, Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, 1873 Rama IV Road Patumwan, Bangkok 10330, Thailand. yong.p@chula.ac.th
Telephone: +66-2-2564909 Fax: +66-2-2564929
Received: July 2, 2018 Peer-review started: July 2, 2018 First decision: July 19, 2018 Revised: August 2, 2018 Accepted: August 6, 2018 Article in press: August 7, 2018 Published online: October 27, 2018 Processing time: 119 Days and 20.8 Hours
Core Tip
Core tip: Adiponectin plays a protective role against the development of liver fibrosis via inhibition of hepatic stellate cell activation, induced by specific signal transduction pathways. Among patients with chronic liver diseases (CLDs), hyperadiponectinemia is associated with the degree of liver fibrosis. The potential link between adiponectin and the limited progression of liver fibrosis has accelerated attraction in seeking adiponectin as a target for diagnostic detection tools and novel treatment methods. Nonetheless, additional current therapeutic and clinical trials of adiponectin in liver fibrosis are needed. In this context, we reviewed additional potential therapeutic applications of adiponectin in patients with various CLDs in the context of liver fibrosis.
